AtonRa Partners Reduces Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

AtonRa Partners lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 10.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,002 shares of the company’s stock after selling 560 shares during the quarter. Neurocrine Biosciences comprises 1.3% of AtonRa Partners’ portfolio, making the stock its 17th largest holding. AtonRa Partners’ holdings in Neurocrine Biosciences were worth $659,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. AE Wealth Management LLC bought a new stake in Neurocrine Biosciences during the 3rd quarter worth approximately $521,000. Asset Management One Co. Ltd. raised its position in shares of Neurocrine Biosciences by 0.5% in the third quarter. Asset Management One Co. Ltd. now owns 38,662 shares of the company’s stock worth $4,349,000 after buying an additional 207 shares in the last quarter. Patriot Financial Group Insurance Agency LLC bought a new stake in Neurocrine Biosciences during the third quarter valued at $206,000. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in Neurocrine Biosciences by 21.1% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 44,700 shares of the company’s stock valued at $5,029,000 after buying an additional 7,800 shares during the period. Finally, Curated Wealth Partners LLC purchased a new position in Neurocrine Biosciences during the third quarter worth about $296,000. 92.59% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Oppenheimer reaffirmed an “outperform” rating and issued a $200.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, April 24th. Mizuho lifted their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research report on Thursday, February 8th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $150.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $142.38.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded up $2.90 during trading hours on Monday, hitting $138.89. The company’s stock had a trading volume of 681,740 shares, compared to its average volume of 845,887. Neurocrine Biosciences, Inc. has a 12 month low of $89.04 and a 12 month high of $148.37. The stock has a market cap of $13.82 billion, a price-to-earnings ratio of 56.19 and a beta of 0.25. The business has a 50-day simple moving average of $136.63 and a 200-day simple moving average of $128.04.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same period last year, the company earned $0.88 EPS. On average, equities research analysts forecast that Neurocrine Biosciences, Inc. will post 4.8 EPS for the current year.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 2,707 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $140.69, for a total value of $380,847.83. Following the completion of the transaction, the chief executive officer now directly owns 502,188 shares in the company, valued at approximately $70,652,829.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 2,707 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total transaction of $380,847.83. Following the transaction, the chief executive officer now owns 502,188 shares in the company, valued at approximately $70,652,829.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric Benevich sold 19,818 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $133.36, for a total value of $2,642,928.48. Following the completion of the transaction, the insider now owns 40,778 shares of the company’s stock, valued at approximately $5,438,154.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 186,994 shares of company stock valued at $25,806,409. 4.30% of the stock is currently owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.